Siemens Healthineers AG appears to be committed to its Diagnostics business after Jochen Schmitz, CFO, pushed back at rumors speculating that the German company was looking at options for the underperforming segment, including a sale.
The artificial intelligence (AI) space doesn’t exactly lack for stakeholders, but the roster of stakeholders in the U.S. is poised to grow by hundreds of millions, according to Laura Adams, senior advisor at the U.S. National Academy of Medicine.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aqtual, Cardiawave, Element Science, Flow Therapy, Route 92.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Biocardia, Brixton, Lunit, Mednition, Vyspine.
Researchers from the Weizmann Institute of Science in Rehovot, Israel, are seeking – through the university’s commercial arm, Yeda Research and Development Co. Ltd. – to gain patent protection for methods and systems for detecting and treating attention deficit hyperactivity disorder (ADHD) that are based on nasal respiration parameters.
Senior leaders and investors in the health care sector expect mergers and acquisitions (M&A) activity to continue to pick up next year but this will be corporate led rather than private equity, according to a report by global investment bank Jefferies. At the same time, many executives remained concerned about the lack of funding in the sector as it was identified as the number one threat.
In the following years, 2023 may come to be seen in medical device circles as the year of artificial intelligence (AI), but that doesn’t mean that 2023 will be seen as the year of regulatory clarity for AI.